Is SPRB or MPLT more profitable?

Maplight Therapeutics' return on equity of -98.60% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -123.53% -90.35% Maplight Therapeutics N/A -98.60% -60.33%

Spruce Biosciences (SPRB) Competitors

$57.93 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

SPRB vs. PRME, MDXG, VALN, ALT, and MPLT

Should you buy Spruce Biosciences stock or one of its competitors? Spruce Biosciences's main competitors and comparable companies include Prime Medicine (PRME), MiMedx Group (MDXG), Valneva (VALN), Altimmune (ALT), and Maplight Therapeutics (MPLT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Spruce Biosciences compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Prime Medicine presently has a consensus target price of $7.47, suggesting a potential upside of 101.95%. Spruce Biosciences has a consensus target price of $159.50, suggesting a potential upside of 175.33%. Given Spruce Biosciences' higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Spruce Biosciences has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	144.95	-$201.14M	-$1.06	N/A
Spruce Biosciences	$4.91M	33.86	-$38.97M	-$39.78	N/A

In the previous week, Prime Medicine had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 2 mentions for Prime Medicine and 0 mentions for Spruce Biosciences. Prime Medicine's average media sentiment score of 0.92 beat Spruce Biosciences' score of -0.80 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Prime Medicine	Positive
Spruce Biosciences	Negative

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 16.0% of Prime Medicine shares are held by insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Prime Medicine has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.31, meaning that its share price is 231% more volatile than the broader market.

Spruce Biosciences has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. Spruce Biosciences' return on equity of -123.53% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
Spruce Biosciences	N/A	-123.53%	-90.35%

Summary

Spruce Biosciences beats Prime Medicine on 9 of the 17 factors compared between the two stocks.

How does Spruce Biosciences compare to MiMedx Group?

Spruce Biosciences (NASDAQ:SPRB) and MiMedx Group (NASDAQ:MDXG) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

MiMedx Group has higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	33.86	-$38.97M	-$39.78	N/A
MiMedx Group	$418.63M	1.59	$48.58M	$0.04	114.25

Spruce Biosciences has a beta of 3.31, suggesting that its share price is 231% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by insiders. Comparatively, 2.5% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Spruce Biosciences presently has a consensus price target of $159.50, suggesting a potential upside of 175.33%. MiMedx Group has a consensus price target of $8.57, suggesting a potential upside of 87.56%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Spruce Biosciences is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, MiMedx Group had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 2 mentions for MiMedx Group and 0 mentions for Spruce Biosciences. MiMedx Group's average media sentiment score of 0.84 beat Spruce Biosciences' score of -0.80 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Spruce Biosciences	Negative
MiMedx Group	Positive

MiMedx Group has a net margin of 1.76% compared to Spruce Biosciences' net margin of 0.00%. MiMedx Group's return on equity of 12.09% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-123.53%	-90.35%
MiMedx Group	1.76%	12.09%	9.22%

Summary

MiMedx Group beats Spruce Biosciences on 9 of the 16 factors compared between the two stocks.

How does Spruce Biosciences compare to Valneva?

Spruce Biosciences (NASDAQ:SPRB) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Spruce Biosciences has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	33.86	-$38.97M	-$39.78	N/A
Valneva	$197.56M	3.31	-$130.33M	-$2.11	N/A

In the previous week, Valneva had 3 more articles in the media than Spruce Biosciences. MarketBeat recorded 3 mentions for Valneva and 0 mentions for Spruce Biosciences. Valneva's average media sentiment score of 0.39 beat Spruce Biosciences' score of -0.80 indicating that Valneva is being referred to more favorably in the news media.

Company	Overall Sentiment
Spruce Biosciences	Negative
Valneva	Neutral

Spruce Biosciences has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Spruce Biosciences' return on equity of -123.53% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-123.53%	-90.35%
Valneva	-110.33%	-153.20%	-39.50%

Spruce Biosciences has a beta of 3.31, meaning that its share price is 231% more volatile than the broader market. Comparatively, Valneva has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

Spruce Biosciences currently has a consensus target price of $159.50, indicating a potential upside of 175.33%. Valneva has a consensus target price of $9.30, indicating a potential upside of 34.98%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Valneva	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 14.9% of Valneva shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Spruce Biosciences beats Valneva on 10 of the 16 factors compared between the two stocks.

How does Spruce Biosciences compare to Altimmune?

Altimmune (NASDAQ:ALT) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Altimmune presently has a consensus target price of $14.33, suggesting a potential upside of 319.10%. Spruce Biosciences has a consensus target price of $159.50, suggesting a potential upside of 175.33%. Given Altimmune's higher probable upside, equities research analysts clearly believe Altimmune is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Spruce Biosciences has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-31.41%	-26.96%
Spruce Biosciences	N/A	-123.53%	-90.35%

78.1% of Altimmune shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 1.6% of Altimmune shares are held by insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Altimmune has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.31, suggesting that its stock price is 231% more volatile than the broader market.

Spruce Biosciences has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	16,631.46	-$88.09M	-$0.78	N/A
Spruce Biosciences	$4.91M	33.86	-$38.97M	-$39.78	N/A

In the previous week, Altimmune had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 2 mentions for Altimmune and 0 mentions for Spruce Biosciences. Altimmune's average media sentiment score of 0.27 beat Spruce Biosciences' score of -0.80 indicating that Altimmune is being referred to more favorably in the media.

Company	Overall Sentiment
Altimmune	Neutral
Spruce Biosciences	Negative

Summary

Spruce Biosciences beats Altimmune on 9 of the 16 factors compared between the two stocks.

How does Spruce Biosciences compare to Maplight Therapeutics?

Spruce Biosciences (NASDAQ:SPRB) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

91.7% of Spruce Biosciences shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Maplight Therapeutics' return on equity of -98.60% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-123.53%	-90.35%
Maplight Therapeutics	N/A	-98.60%	-60.33%

Spruce Biosciences has higher revenue and earnings than Maplight Therapeutics. Spruce Biosciences is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	33.86	-$38.97M	-$39.78	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A

In the previous week, Maplight Therapeutics had 3 more articles in the media than Spruce Biosciences. MarketBeat recorded 3 mentions for Maplight Therapeutics and 0 mentions for Spruce Biosciences. Maplight Therapeutics' average media sentiment score of -0.12 beat Spruce Biosciences' score of -0.80 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Spruce Biosciences	Negative
Maplight Therapeutics	Neutral

Spruce Biosciences presently has a consensus price target of $159.50, indicating a potential upside of 175.33%. Maplight Therapeutics has a consensus price target of $29.50, indicating a potential upside of 114.23%. Given Spruce Biosciences' higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94

Summary

Spruce Biosciences and Maplight Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Spruce Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRB vs. The Competition

Export

Metric	Spruce Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$166.26M	$3.99B	$7.21B	$12.89B
Dividend Yield	N/A	3.60%	2.54%	9.13%
P/E Ratio	-1.46	12.71	273.84	25.45
Price / Sales	33.86	1,344.26	625.55	100.83
Price / Cash	N/A	45.00	28.92	35.62
Price / Book	1.46	16.39	11.01	6.39
Net Income	-$38.97M	-$22.85M	$3.49B	$358.69M
7 Day Performance	-1.76%	1.43%	1.63%	0.22%
1 Month Performance	23.60%	6.00%	4.42%	-0.10%
1 Year Performance	543.67%	49.38%	24.21%	14.04%

Spruce Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRB Spruce Biosciences	2.5082 of 5 stars	$57.93 flat	$159.50 +175.3%	+543.7%	$166.26M	$4.91M	N/A	20
PRME Prime Medicine	2.795 of 5 stars	$3.70 -0.4%	$7.47 +102.2%	-0.5%	$670.20M	$4.63M	N/A	N/A	Gap Up
MDXG MiMedx Group	2.4966 of 5 stars	$4.58 +3.3%	$8.57 +87.4%	-36.0%	$666.85M	$418.63M	114.40	870	Positive News
VALN Valneva	2.0932 of 5 stars	$6.96 -1.4%	$9.30 +33.6%	-20.3%	$658.54M	$197.56M	N/A	700
ALT Altimmune	2.369 of 5 stars	$3.38 +4.5%	$14.33 +324.7%	-9.5%	$656.51M	$40K	N/A	50	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRB) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spruce Biosciences (SPRB) Competitors

SPRB vs. PRME, MDXG, VALN, ALT, and MPLT

How does Spruce Biosciences compare to Prime Medicine?

Summary

How does Spruce Biosciences compare to MiMedx Group?

Summary

How does Spruce Biosciences compare to Valneva?

Summary

How does Spruce Biosciences compare to Altimmune?

Summary

How does Spruce Biosciences compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spruce Biosciences (SPRB) Competitors

SPRB vs. PRME, MDXG, VALN, ALT, and MPLT

How does Spruce Biosciences compare to Prime Medicine?

Do analysts rate PRME or SPRB?

Which has higher valuation & earnings, PRME or SPRB?

Does the media prefer PRME or SPRB?

Do institutionals & insiders have more ownership in PRME or SPRB?

Which has more volatility & risk, PRME or SPRB?

Is PRME or SPRB more profitable?

Summary

How does Spruce Biosciences compare to MiMedx Group?

Which has stronger earnings & valuation, SPRB or MDXG?

Which has more risk & volatility, SPRB or MDXG?

Do institutionals and insiders have more ownership in SPRB or MDXG?

Do analysts prefer SPRB or MDXG?

Does the media favor SPRB or MDXG?

Is SPRB or MDXG more profitable?

Summary

How does Spruce Biosciences compare to Valneva?

Which has preferable earnings and valuation, SPRB or VALN?

Does the media refer more to SPRB or VALN?

Is SPRB or VALN more profitable?

Which has more volatility & risk, SPRB or VALN?

Do analysts prefer SPRB or VALN?

Do insiders and institutionals believe in SPRB or VALN?

Summary

How does Spruce Biosciences compare to Altimmune?

Do analysts recommend ALT or SPRB?

Is ALT or SPRB more profitable?

Do insiders & institutionals hold more shares of ALT or SPRB?

Which has more volatility & risk, ALT or SPRB?

Which has higher earnings & valuation, ALT or SPRB?

Does the media prefer ALT or SPRB?

Summary

How does Spruce Biosciences compare to Maplight Therapeutics?

Do insiders and institutionals hold more shares of SPRB or MPLT?

Is SPRB or MPLT more profitable?

Which has stronger earnings & valuation, SPRB or MPLT?

Does the media favor SPRB or MPLT?

Do analysts prefer SPRB or MPLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools